MGI(SH:688114) Bei Jing Shang Bao·2026-02-23 09:48Core Viewpoint - The company, BGI Genomics, is divesting its subsidiary Complete Genomics, Inc. (CGI) to Swiss Rockets AG for approximately $50 million, which is expected to enhance its financial performance and operational efficiency [1][2]. Group 1: Transaction Details - BGI Genomics' subsidiary MGI Tech R&D Hong Kong Co., Limited has signed a share purchase agreement to sell 100% of CGI after stripping it of related assets and liabilities for about $50 million [1]. - Prior to the transaction, CGI has entered into a reverse licensing agreement with MGI US LLC, permanently and irrevocably licensing 205 patents, trade secrets, and trademarks to MGI US LLC [1]. Group 2: Financial Implications - The transaction is anticipated to generate significant direct revenue and improve cash flow for the company, with an expected income of approximately $50 million from the sale [2]. - By divesting the loss-making business unit, the company expects to reduce annual losses attributed to that unit, thereby substantially enhancing overall profitability and operational efficiency [2]. - The licensing arrangement will provide the company with a tiered revenue share based on the future global net sales of the licensed products, contributing to a stable and sustainable long-term cash flow source [2].